AbbVie sees a world according to GARP
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
J&J deal cements Ambrx’s transformation
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
